New treatment tested for rare Muscle-Weakening disease in kids

NCT ID NCT06149559

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

Summary

This study is testing an investigational drug called rozanolixizumab in children aged 2 to 18 who have moderate to severe generalized myasthenia gravis (gMG), a rare autoimmune disease that causes muscle weakness. The main goal is to see if the drug is safe and well-tolerated when given as a subcutaneous injection (under the skin) over a 6-week treatment period. Researchers will also measure if the drug helps reduce disease symptoms and lowers the levels of harmful antibodies in the blood.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mg0006 20081
RECRUITING

Taipei, Taiwan
Mg0006 20095
RECRUITING

Taipei, Taiwan
Mg0006 20339
RECRUITING

Ōbu, Japan
Mg0006 20340
RECRUITING

Fuchu-shi, Japan
Mg0006 20343
RECRUITING

Sagamihara, Japan
Mg0006 40144
RECRUITING

Milan, Italy
Mg0006 40155
RECRUITING

Warsaw, Poland
Mg0006 40290
RECRUITING

Bologna, Italy
Mg0006 40733
RECRUITING

Naples, Italy
Mg0006 40734
RECRUITING

Warsaw, Poland
Mg0006 40836
RECRUITING

Kocaeli, Turkey (Türkiye)
Mg0006 40841
RECRUITING

Altindağ/ankara, Turkey (Türkiye)
Mg0006 50574
WITHDRAWN

Flower Mound, Texas, 75028, United States

Conditions

Explore the condition pages connected to this study.

GENERALIZED MYASTHENIA GRAVIS